Cytel to acquire SDS Life Science and SDS MedteQ
The move will add new global talent to Cytel’s Strategic Consulting group
The move will add new global talent to Cytel’s Strategic Consulting group
Plans to double its manufacturing footprint to bolster the growth
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Funds raised will be used to develop technology and foster healthcare partnerships
Subscribe To Our Newsletter & Stay Updated